Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX Combined With Lenvatinib and Toripalimab for Advanced Cholangiocarcinoma
NCT05215665Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of lenvatinib in cholangiocarcinoma (CCA) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Overall Response Rate. Started Jan 2022; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05215665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215665.